Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Elotuzumab - AbbVie/Bristol-Myers Squibb

Next Previous
Drug Profile

Elotuzumab - AbbVie/Bristol-Myers Squibb

Alternative Names: BMS-901608; Empliciti; HuLuc-63; PDL-063

Latest Information Update: 02 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PDL BioPharma
  • Developer AbbVie; Australasian Leukaemia & Lymphoma Group; Bristol-Myers Squibb
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple myeloma
  • Phase II Smoldering multiple myeloma

Most Recent Events

  • 23 Feb 2026 Bristol-Myers Squibb completes a phase II trial in Multiple Myeloma (Combination therapy, Second line therapy or greater) in USA, Australia, Belgium, Canada, Greece, Hungary, Italy, Japan, Poland, Romania, Spain, Turkey and UK (IV) (NCT02719613)
  • 01 Dec 2025 University of Chicago, Bristol-Myers Squibb and Amgen completes a phase II trial for Multiple myeloma (Combination therapy, First-line therapy, Newly diagnosed) in USA (IV) (NCT02969837)
  • 14 Feb 2025 Bristol-Myers Squibb completes the phase II trial in Multiple myeloma (Second-line or greater therapy, Combination therapy) in USA (IV) (NCT03361306)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top